AU2021208493B2 - FimH mutant, compositions therewith and use thereof - Google Patents

FimH mutant, compositions therewith and use thereof Download PDF

Info

Publication number
AU2021208493B2
AU2021208493B2 AU2021208493A AU2021208493A AU2021208493B2 AU 2021208493 B2 AU2021208493 B2 AU 2021208493B2 AU 2021208493 A AU2021208493 A AU 2021208493A AU 2021208493 A AU2021208493 A AU 2021208493A AU 2021208493 B2 AU2021208493 B2 AU 2021208493B2
Authority
AU
Australia
Prior art keywords
polypeptide
fimh
lectin domain
polynucleotide
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021208493A
Other languages
English (en)
Other versions
AU2021208493A1 (en
Inventor
Kellen Cristhina Fae
Louris Jakob Feitsma
Jeroen GEURTSEN
Jan GRIJPSTRA
Eveline Marleen WEERDENBURG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AU2021208493A1 publication Critical patent/AU2021208493A1/en
Application granted granted Critical
Publication of AU2021208493B2 publication Critical patent/AU2021208493B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021208493A 2020-01-16 2021-01-14 FimH mutant, compositions therewith and use thereof Active AU2021208493B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20152217 2020-01-16
EP20152217.4 2020-01-16
PCT/EP2021/050707 WO2021144369A1 (en) 2020-01-16 2021-01-14 Fimh mutant, compositions therewith and use thereof

Publications (2)

Publication Number Publication Date
AU2021208493A1 AU2021208493A1 (en) 2022-06-30
AU2021208493B2 true AU2021208493B2 (en) 2023-03-30

Family

ID=69174406

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021208493A Active AU2021208493B2 (en) 2020-01-16 2021-01-14 FimH mutant, compositions therewith and use thereof

Country Status (25)

Country Link
US (3) US11421003B2 (enExample)
EP (2) EP4090363B1 (enExample)
JP (2) JP7485771B2 (enExample)
KR (1) KR20220128372A (enExample)
CN (1) CN115038461A (enExample)
AR (1) AR121066A1 (enExample)
AU (1) AU2021208493B2 (enExample)
BR (1) BR112022013720A2 (enExample)
CA (1) CA3168108A1 (enExample)
DK (1) DK4090363T3 (enExample)
ES (1) ES2987890T3 (enExample)
FI (1) FI4090363T3 (enExample)
HR (1) HRP20241370T1 (enExample)
HU (1) HUE068985T2 (enExample)
IL (1) IL294445B2 (enExample)
LT (1) LT4090363T (enExample)
MX (1) MX2022008830A (enExample)
MY (1) MY209568A (enExample)
PL (1) PL4090363T3 (enExample)
PT (1) PT4090363T (enExample)
RS (1) RS66031B1 (enExample)
SA (1) SA522433319B1 (enExample)
SI (1) SI4090363T1 (enExample)
TW (1) TWI868297B (enExample)
WO (1) WO2021144369A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
BR112022014555A2 (pt) 2020-02-23 2022-09-20 Pfizer Composições de escherichia coli e métodos das mesmas.
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) * 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022153166A1 (en) * 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
JP2025503423A (ja) * 2021-12-17 2025-02-04 ファイザー・インク ポリヌクレオチド組成物およびその使用
CN119212720A (zh) 2022-05-25 2024-12-27 库瑞瓦格欧洲股份公司 编码大肠杆菌FimH抗原性多肽的基于核酸的疫苗
JP7656656B2 (ja) * 2022-06-20 2025-04-03 ファイザー・インク 大腸菌ＦｉｍＨ変異体およびその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ATE278419T1 (de) 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
WO2001025254A2 (en) 1999-10-04 2001-04-12 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
ATE398463T1 (de) 2000-04-13 2008-07-15 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
JP2004502447A (ja) 2000-07-07 2004-01-29 メディミューン，インコーポレイテッド ＦｉｍＨアドへシンタンパク質および使用方法
CA2420234A1 (en) 2000-08-18 2002-02-28 Medimmune, Inc. Method of administering fimh protein as a vaccine for urinary tract infections
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
AU2006241206B2 (en) 2005-04-26 2011-06-09 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
WO2006119987A2 (en) 2005-05-11 2006-11-16 ETH Zürich Recombinant n-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2716187C (en) 2008-02-20 2020-01-07 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
DK2811981T3 (da) 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) * 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
RS65631B1 (sr) 2014-02-24 2024-07-31 Glaxosmithkline Biologicals Sa Novi polisaharid i njegove upotrebe
EP3294761A4 (en) * 2015-05-13 2019-04-03 University of Washington COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
US20190275135A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against intra-abdominal infections
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure

Also Published As

Publication number Publication date
MY209568A (en) 2025-07-22
EP4461744A2 (en) 2024-11-13
HUE068985T2 (hu) 2025-02-28
US11421003B2 (en) 2022-08-23
LT4090363T (lt) 2024-09-25
SA522433319B1 (ar) 2024-07-10
TWI868297B (zh) 2025-01-01
DK4090363T3 (da) 2024-09-30
FI4090363T3 (fi) 2024-09-25
JP7485771B2 (ja) 2024-05-16
SI4090363T1 (sl) 2024-10-30
AU2021208493A1 (en) 2022-06-30
HRP20241370T1 (hr) 2024-12-20
IL294445A (en) 2022-09-01
PL4090363T3 (pl) 2024-11-25
JP2024045126A (ja) 2024-04-02
WO2021144369A1 (en) 2021-07-22
EP4090363B1 (en) 2024-09-04
EP4461744A3 (en) 2025-01-08
JP2023500749A (ja) 2023-01-10
AR121066A1 (es) 2022-04-13
US20240294582A1 (en) 2024-09-05
IL294445B1 (en) 2023-06-01
RS66031B1 (sr) 2024-11-29
CN115038461A (zh) 2022-09-09
ES2987890T3 (es) 2024-11-18
US20210221856A1 (en) 2021-07-22
PT4090363T (pt) 2024-09-19
EP4090363A1 (en) 2022-11-23
CA3168108A1 (en) 2021-07-22
US12012435B2 (en) 2024-06-18
BR112022013720A2 (pt) 2022-10-11
US12428449B2 (en) 2025-09-30
IL294445B2 (en) 2023-10-01
TW202140521A (zh) 2021-11-01
US20230049056A1 (en) 2023-02-16
KR20220128372A (ko) 2022-09-20
MX2022008830A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
AU2021208493B2 (en) FimH mutant, compositions therewith and use thereof
US12297238B2 (en) FimH mutants, compositions therewith and use thereof
HK40118175A (en) Fimh mutant, compositions therewith and use thereof
HK40084704B (en) Fimh mutant, compositions therewith and use thereof
HK40084704A (en) Fimh mutant, compositions therewith and use thereof
EA047213B1 (ru) Мутантная форма fimh, композиции на ее основе и их применение
EA050404B1 (ru) Мутанты fimh, композиции с ними и их применение

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)